伟思医疗(688580.SH):2025年三季报净利润为1.02亿元

Core Insights - The company reported a total revenue of 326 million yuan for Q3 2025, with a net profit attributable to shareholders of 102 million yuan and a net cash inflow from operating activities of 104 million yuan [1]. Financial Performance - The latest debt-to-asset ratio stands at 9.06%, which is an increase of 0.11 percentage points from the previous quarter [3]. - The gross profit margin is reported at 66.86% [3]. - The return on equity (ROE) is 6.16% [3]. - The diluted earnings per share (EPS) is 1.07 yuan [3]. - The total asset turnover ratio is 0.18 times, while the inventory turnover ratio is 2.56 times [3]. Shareholder Information - The number of shareholders is 8,098, with the top ten shareholders holding a total of 66.35 million shares, accounting for 69.28% of the total share capital [3]. - The top shareholders include: - Wang Zhiyu: 39.4% - Hu Ping: 16.4% - Nanjing Zhida Venture Capital Center (Limited Partnership): 8.15% - Shenzhen Yanghe Biomedical Industry Investment Co., Ltd.: 1.18% - Feng Lixia: 0.93% - Zhao Guangming: 0.78% - Shen Tao: 0.74% - Hu Jun: 0.58% - Yu Fenghua: 0.57% - Fan Lili: 0.49% [3].